Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.

Trial Details

NCT ID
NCT07358195
Phase
EARLY_PHASE1
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Venetoclax
  • Hematopoietic Cell Transplantation Conditioning Regimen
  • Kidney Transplant
  • Hematopoietic Cell Transplantation
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Patient ages 18-70
  • Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT vot…
  • Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous l…
  • Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →